Study of Efficacy and Safety of ABO809 in Healthy Participants
Cryptosporidium Infection, Cryptosporidiosis
About this trial
This is an interventional other trial for Cryptosporidium Infection, Cryptosporidiosis focused on measuring Controlled Human Infection Model, CHIM, infection, diarrhea, safety, tolerability, healthy volunteers, Phase I, cryptosporidiosis, Cryptosporidium, oral, ABO809
Eligibility Criteria
Inclusion Criteria:
- Demonstrated understanding of Cryptosporidium disease, safety measures and transmission risks
- Good health
- Ability to communicate well with the Investigator
Exclusion Criteria:
- History of Cryptosporidium infection, gastrointestinal conditions (including diarrheal syndromes, gastroenteritis and gastrointestinal tract surgery), immunodeficiency, infections, significant medical concerns, hypersensitivity to nitazoxanide or other specified antibiotics.
Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Novartis Investigative Site
Arms of the Study
Arm 1
Experimental
ABO809
Participants will receive ABO809 at a single oral dose of 1x10^4 oocysts. Other doses such as 1x10^6 oocysts may be considered to optimize the model